Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CYT-0851, its investigational monocarboxylate transporter inhibitor, which is investigated combination study with capecitabine or gemcitabine in advanced ovarian cancer and other solid tumors.
Lead Product(s): Rad51-IN-2,Capecitabine
Therapeutic Area: Oncology Product Name: CYT-0851
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Product is being investigation in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.
Lead Product(s): Rad51-IN-2,Capecitabine
Therapeutic Area: Oncology Product Name: CYT-0851
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
CYT-0851 is in a Phase 1/2 clinical trial as both a monotherapy and in combination with standard of care chemotherapy and has the potential to be a first-in-class MCT inhibitor. By impairing monocarboxylate transporter-mediated lactate transport, CYT-0851 disrupts glycolysis.
Lead Product(s): Rad51-IN-2,Rituximab,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: CYT-0851
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Data for CYT-0851 show that the drug has performed well in cancer patients: it has desirable pharmacologic properties with an estimated half-life of three days, dose proportional exposure, and a dose dependent, predictable, and favorable safety profile.
Lead Product(s): Rad51-IN-2,Rituximab,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: CYT-0851
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
Proceeds will support monotherapy and combination therapy trials of first-in-class RAD51 inhibitor CYT-0851, as well as fund R&D for novel synthetic lethal cancer targets.
Lead Product(s): Rad51-IN-2
Therapeutic Area: Oncology Product Name: CYT-0851
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing February 11, 2021
Details:
The Phase 1 study will evaluate the safety and tolerability of CYT-0851 as monotherapy and identify the recommended dose for phase 2 and future studies.
Lead Product(s): Rad51-IN-2
Therapeutic Area: Oncology Product Name: CYT-0851
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020